<DOC>
	<DOCNO>NCT02115659</DOCNO>
	<brief_summary>Triptolide show experimental study inhibit cyst formation growth ADPKD model , triptolide-containing formulation reveal potentially slow disease progression several proteinuric ADPKD patient clinical practice . It remain show effect triptolide-containing formulation total kidney volume ( TKV ) enlargement renal function protection ADPKD patient .</brief_summary>
	<brief_title>Triptolide-Containing Formulation Treatment Autosomal Dominant Polycystic Kidney Disease ( ADPKD )</brief_title>
	<detailed_description>Randomized Controlled Trial</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Triptolide</mesh_term>
	<criteria>ADPKD patient old 40 year age without gender limitation Estimated glomerular filtration rate ( eGFR ) high 60 ml/min 1.73m2 documented kidney volume progression yearly increase rate 6 % informed consent Female planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception impair liver function increase liver enzymes ( 2fold normal value ) uncontrolled hypercholesterolemia ( fast cholesterol &gt; 8 mmol/l ) hypertriglyceridaemia ( &gt; 5 mmol/l ) lipid lower therapy granulocytopenia ( white blood cell &lt; 3,000/mm3 ) thrombocytopenia ( platelet &lt; 100,000/mm3 ) hepatitis B C , HIV infection malignancy mental illness interfere patient ability comply protocol drug alcohol abuse know hypersensitivity similar drug TriptolideContaining Formulation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>triptolide</keyword>
</DOC>